- Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
-
Kim YJ, Ji WJ, Lee JC, Chun SM, Choi CM
- KMID: 2534178
- Cancer Res Treat.
- 2022 Oct;54(4):985-995.
- doi: 10.4143/crt.2021.857
Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF)... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
-
Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, Kim YM, Jung JS, Kang Y, Ji W, Choi MG, Lee JC, Rho JK, Choi CM
- KMID: 2534180
- Cancer Res Treat.
- 2022 Oct;54(4):1005-1016.
- doi: 10.4143/crt.2021.986
Purpose The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized... -
- CITED
-
- Close
- SHARE
-
- Close
- The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer
-
Chae KJ, Choi H, Jeong WG, Kim J
- KMID: 2534179
- Cancer Res Treat.
- 2022 Oct;54(4):996-1004.
- doi: 10.4143/crt.2021.902
Purpose The illness-death model (IDM) is a comprehensive approach to evaluate the relationship between relapse and death. This study aimed to illustrate the value of the IDM for identifying risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer
-
Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, Lee DH
- KMID: 2531323
- Cancer Res Treat.
- 2022 Jul;54(3):767-781.
- doi: 10.4143/crt.2021.651
Purpose Heat shock protein-90 (HSP90) remains an important cancer target because of its involvement in multiple oncogenic protein pathways and biologic processes. Although many HSP90 inhibitors have been tested in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
-
Rivera-Concepcion J, Uprety D, Adjei AA
- KMID: 2528202
- Cancer Res Treat.
- 2022 Apr;54(2):315-329.
- doi: 10.4143/crt.2022.078
Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage NSCLC. Increasing... -
- CITED
-
- Close
- SHARE
-
- Close
- miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
-
Kim MS, Kim SH, Yang SH, Kim MS
- KMID: 2528214
- Cancer Res Treat.
- 2022 Apr;54(2):445-457.
- doi: 10.4143/crt.2021.622
Purpose With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma
-
Mehta A, Diwan H, Bansal D, Gupta M
- KMID: 2524230
- J Pathol Transl Med.
- 2022 Jan;56(1):53-56.
- doi: 10.4132/jptm.2021.09.16
SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non–small cell lung carcinomas. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
-
Lee C, Kim M, Kim DW, Kim TM, Kim S, Im SW, Jeon YK, Keam B, Ku JL, Heo DS
- KMID: 2524595
- Cancer Res Treat.
- 2022 Jan;54(1):140-149.
- doi: 10.4143/crt.2021.385
Purpose Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non–small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance... -
- CITED
-
- Close
- SHARE
-
- Close
- Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
-
Garg G, Prasad KT, Singh N, Gupta P, Muthu V, Das A, Bal A
- KMID: 2522441
- J Pathol Transl Med.
- 2021 Nov;55(6):398-405.
- doi: 10.4132/jptm.2021.08.08
Background: Data on the prevalence of programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in non–small cell lung cancer (NSCLC) and their clinical significance in Indian patients are limited.... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer
-
Yoo YJ, Kim SS, Song SY, Kim JH, Ahn SD, Lee Sw, Yoon SM, Kim YS, Park Jh, Jung J, Choi EK
- KMID: 2520456
- Radiat Oncol J.
- 2021 Sep;39(3):202-209.
- doi: 10.3857/roj.2021.00416
Purpose: To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT)... -
- CITED
-
- Close
- SHARE
-
- Close
- SMARCA4/BRG1 protein-deficient thoracic tumors dictate re-examination of small biopsy reporting in non–small cell lung cancer
-
Mehta A, Bansal D, Tripathi R, Jajodia A
- KMID: 2520169
- J Pathol Transl Med.
- 2021 Sep;55(5):307-316.
- doi: 10.4132/jptm.2021.05.11
Background: SMARCA4/BRG1 protein–deficient lung adenocarcinomas and thoracic sarcoma are recently described entities that lack distinctive histological features, transcription termination factor 1 (TTF1) reactivity, and actionable driver mutations. The current diagnostic... -
- CITED
-
- Close
- SHARE
-
- Close
- Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
-
Shin H, Noh JM, Pyo H, Ahn YC, Oh D
- KMID: 2514511
- Radiat Oncol J.
- 2021 Mar;39(1):24-32.
- doi: 10.3857/roj.2020.01074
Purpose: This study aimed to evaluate the clinical outcomes and toxicities of salvage proton beam therapy (PBT) in patients with locoregional recurrent non-small cell lung cancer (NSCLC). Materials and Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
-
Lee SY, Hong YK, Ji W, Lee JC, Choi CM, Korean Association for Lung Cancer, Korea Central Cancer Registry
- KMID: 2510652
- Cancer Res Treat.
- 2021 Jan;53(1):104-111.
- doi: 10.4143/crt.2020.894
Purpose As the aging of society progresses, the proportion of extremely older lung cancer patients has also increased; However, studies of these patients with non–small cell lung cancer are limited. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
-
Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC
- KMID: 2510651
- Cancer Res Treat.
- 2021 Jan;53(1):93-103.
- doi: 10.4143/crt.2020.459
Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in... -
- CITED
-
- Close
- SHARE
-
- Close
- An Unusual Case of Metastatic Non-Small Cell Lung Cancer Misidentified as Anaplastic Thyroid Cancer
-
Ko HM, Kim JR
- KMID: 2509203
- Int J Thyroidol.
- 2020 Nov;13(2):170-174.
- doi: 10.11106/ijt.2020.13.2.170
Metastases from other organs to the thyroid are considered to be extremely rare. Among thyroid malignancies, anaplastic thyroid cancer exhibits similar features to a number of other cancers and can... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
-
Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS
- KMID: 2454300
- Cancer Res Treat.
- 2019 Jul;51(3):1086-1097.
- doi: 10.4143/crt.2018.537
PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression... -
- CITED
-
- Close
- SHARE
-
- Close
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
-
Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS
- KMID: 2454287
- Cancer Res Treat.
- 2019 Jul;51(3):951-962.
- doi: 10.4143/crt.2018.052
PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
-
Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC
- KMID: 2464423
- Cancer Res Treat.
- 2019 Apr;51(2):777-787.
- doi: 10.4143/crt.2018.387
PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib... -
- CITED
-
- Close
- SHARE
-
- Close
- Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
-
Lee KH, Ahn YC, Pyo H, Noh JM, Park SG, Kim TG, Lee E, Nam H, Lee H, Sun JM, Ahn JS, Ahn MJ, Park K
- KMID: 2464422
- Cancer Res Treat.
- 2019 Apr;51(2):769-776.
- doi: 10.4143/crt.2018.366
PURPOSE: This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. MATERIALS... -
- CITED
-
- Close
- SHARE
-
- Close
- A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
-
Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
- KMID: 2464417
- Cancer Res Treat.
- 2019 Apr;51(2):718-726.
- doi: 10.4143/crt.2018.324
PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor... -
- CITED
-
- Close
- SHARE
-
- Close
